herpes
GSK’s Arexvy RSV vaccine receives expanded EC approval for use in adults
RSV affects approximately 64 million people around the world each year
FDA approves Pfizer and BioNTech’s jab for COVID-19
Globally, five billion doses of the companies’ vaccine have been distributed
Pfizer’s RSV vaccine candidate accepted for FDA priority review for use in older adults
A phase 3 study showed the vaccine was 85.7% effective in those with three or more symptoms
Moderna’s bivalent Omicron-targeting boosters show superiority to original COVID-19 vaccine
Both boosters produced a better immune response against Omicron BA.4/BA.5 subvariants
Pfizer’s maternal RSV vaccine candidate shows promise in phase 3 trial
The company stopped the trial early and plans to file for US approval by the end of 2022
GSK’s respiratory syncytial virus older adult vaccine given Priority Review by FDA
There are currently no RSV vaccines approved for older adults anywhere worldwide
GSK’s application for its RSV vaccine accepted by EMA under accelerated assessment
The vaccine demonstrated overall efficacy of 82.5% in adults aged 60 years and older
GSK’s shingles vaccine demonstrates at least ten-year efficacy in long-term study
ZOSTER-049 follows participants from two phase 3 trials for an additional six years
Pfizer/BioNTech announce positive early data from trial of BA.4/BA.5 COVID-19 booster
A 30µg dose of the booster demonstrated a ‘substantial increase’ in antibody response
WHO announces recommended 2023 flu vaccines for southern hemisphere
The constantly evolving nature of influenza viruses requires frequent reformulation of vaccines
Pfizer doses first patients with mRNA-based influenza vaccine
Available vaccine strains that match circulating influenza viruses offer only 40%-60% protection
Moderna sues Pfizer/BioNTech over COVID-19 vaccine technology
The company believes two key features of its patented mRNA technology platform were copied